Brief: Nextcure And Simcere Zaiming Announce Strategic Partnership For A Novel Antibody-Drug Conjugate Targeting CDH6
16/06/2025 12:42
June 16 (Reuters) - Simcere Pharmaceutical Group Ltd 2096.HK: NEXTCURE AND SIMCERE ZAIMING ANNOUNCE STRATEGIC PARTNERSHIP FOR A NOVEL ANTIBODY-DRUG CONJUGATE TARGETING CDH6 NEXTCURE INC - GAINS GLOBAL RIGHTS TO SIM0505 EXCLUDING GREATER CHINA NEXTCURE INC - U.S. PHASE 1 CLINICAL TRIAL FOR SIM0505 TO BEGIN Q3 2025 NEXTCURE INC - SIMCERE ZAIMING ELIGIBLE FOR PAYMENTS UP TO $745M AND ROYALTIES NEXTCURE INC - INITIAL PHASE 1 CLINICAL DATA EXPECTED IN FIRST HALF OF 2026 Source text: ID:nGNX46FtV8 Further company coverage: 2096.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660